AR081832A1 - Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR081832A1 AR081832A1 ARP110101901A ARP110101901A AR081832A1 AR 081832 A1 AR081832 A1 AR 081832A1 AR P110101901 A ARP110101901 A AR P110101901A AR P110101901 A ARP110101901 A AR P110101901A AR 081832 A1 AR081832 A1 AR 081832A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- group
- hydroxy
- fluoroalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Compuestos que responden a la fórmula general (1) en la que R2 representa: un grupo alquilo C1-10, cicloalquil C3-7-alquilo C1-6, alquiltio C1-6-alquilo C1-10, alcoxi C1-6-alquilo C1-10, hidroxi-alquilo C1-10, hidroxi-alquil C1-6-cicloalquilo C3-7-alquilo C1-6, fluoroalquilo C1-10, alquil C1-10-oxiimino-alquilo C1-10; un grupo cicloalquilo C3-10, fluorocicloalquilo C3-10, hidroxi-cicloalquilo C3-10; un grupo cicloalquilo C3-7 que puede estar sustituido con uno o dos grupos elegidos independientemente entre alquilo C1-6, cicloalquilo C3-7, hidroxi, fluoroalquilo C1-10 o alquil C1-10-oxiimino; un grupo heterocíclico que contiene de 3 a 8 átomos de carbono y al menos un heteroátomo elegido entre nitrógeno, oxigeno, azufre y la forma oxidada o dioxidada del azufre, pudiendo estar este grupo heterocíclico sustituido con uno o varios grupos hidroxi, alquilo C1-6, hidroxi-alquilo C1-6, fluoroalquilo C1-6; un grupo alquilo C1-10 sustituido con un grupo heterocíclico que contiene de 3 a 8 átomos de carbono y al menos un heteroátomo elegido entre nitrógeno, oxígeno, azufre y la forma oxidada o dioxidada del azufre, pudiendo estar este grupo heterocíclico sustituido con uno o varios grupos hidroxi, alquilo C1-6, hidroxi-alquilo C1-6, fluoroalquilo C1-6; X6 representa un átomo de hidrógeno, de flúor, de cloro, de bromo o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6, fluoroalquilo C1-6 o ciano; R7 representa un grupo fenilo o un grupo naftilo, sustituido opcionalmente con uno o varios sustituyentes X7, idénticos o diferentes, elegidos independientemente; X7 representa: un átomo de halógeno elegido entre el átomo de flúor, cloro o bromo, o un grupo elegido entre: hidroxi; alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-6; hidroxi-alquilo C1-6, hidroxi-cicloalquilo C3-7, hidroxi-cicloalquil C3-7-alquilo C1-6; alcoxi C1-6, cicloalcoxi C3-7, cicloalquil C3-7-alcoxi C1-6; alquiltio C1-6, cicloalquiltio C3-7, cicloalquil C3-7-alquiltio C1-6; arilo, aril-alquilo C1-6; ariloxi, aril-alcoxi C1-6; fluoroalquilo C1-6, fluorocicloalquilo C3-7, fluorocicloalquil C3-7-alquilo C1-6; fluoroalcoxi C1-6, fluorocicloalcoxi C3-7, fluorocicloalquil C3-7-alcoxi C1-6; ciano, ciano-alquilo C1-6, ciano-alcoxi C1-6; NRaRb, NRcCORd, NRcSO2Rd, NRcSO2NRaRb, CONRaRb, CON(ORc)Rd; un grupo heteroarilo, estando los grupos arilo o heteroarilo sustituidos opcionalmente con uno o varios sustituyentes elegidos entre el átomo de flúor, de cloro o de bromo o un grupo alquilo C1-6, cicloalquilo C3-7, alcoxi C1-6, fluoroalquilo C1-6, fluoroalcoxi C1-6 o ciano; Ra y Rb representan independientemente el uno del otro un átomo de hidrógeno o un grupo alquilo C1-6, cicloalquilo C3-7 o cicloalquil C3-7-alquilo C1-6, o bien forman con el átomo al que están unidos un ciclo elegido entre azetidina, pirrolidina, piperidina, morfolina, tiomorfolina, azepina, piperazina, estando este ciclo sustituido opcionalmente con uno o varios grupos alquilo C1-6; Rc y Rd representan independientemente el uno del otro un átomo de hidrógeno o un grupo alquilo C1-6, cicloalquilo C3-7 o cicloalquil C3-7-alquilo C1-6; en el estado de base o de sal de adición a un ácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1054372A FR2960876B1 (fr) | 2010-06-03 | 2010-06-03 | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081832A1 true AR081832A1 (es) | 2012-10-24 |
Family
ID=42697541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101901A AR081832A1 (es) | 2010-06-03 | 2011-06-02 | Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida, su preparacion y su aplicacion en terapeutica |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8791119B2 (es) |
| EP (1) | EP2588480B1 (es) |
| JP (1) | JP5995841B2 (es) |
| KR (1) | KR20130113928A (es) |
| CN (1) | CN103168041B (es) |
| AR (1) | AR081832A1 (es) |
| AU (1) | AU2011268651B2 (es) |
| BR (1) | BR112012030697A2 (es) |
| CA (1) | CA2801154C (es) |
| CL (1) | CL2012003360A1 (es) |
| CO (1) | CO6602113A2 (es) |
| CR (1) | CR20120595A (es) |
| CY (1) | CY1118512T1 (es) |
| DK (1) | DK2588480T3 (es) |
| DO (1) | DOP2012000296A (es) |
| EA (1) | EA201291364A1 (es) |
| EC (1) | ECSP12012322A (es) |
| ES (1) | ES2603420T3 (es) |
| FR (1) | FR2960876B1 (es) |
| GT (1) | GT201200319A (es) |
| HR (1) | HRP20161494T1 (es) |
| HU (1) | HUE030650T2 (es) |
| IL (1) | IL223364A (es) |
| LT (1) | LT2588480T (es) |
| MA (1) | MA34360B1 (es) |
| MX (1) | MX2012014084A (es) |
| NI (1) | NI201200176A (es) |
| NZ (1) | NZ603947A (es) |
| PE (1) | PE20130259A1 (es) |
| PL (1) | PL2588480T3 (es) |
| PT (1) | PT2588480T (es) |
| SG (1) | SG186143A1 (es) |
| SI (1) | SI2588480T1 (es) |
| TN (1) | TN2012000520A1 (es) |
| TW (1) | TWI487707B (es) |
| UY (1) | UY33428A (es) |
| WO (1) | WO2011161537A2 (es) |
| ZA (1) | ZA201209071B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| UY35834A (es) * | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
| JP6307989B2 (ja) * | 2014-04-02 | 2018-04-11 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| CN110709523B (zh) * | 2017-04-12 | 2023-07-11 | 豪夫迈·罗氏有限公司 | 使用经pictet spengler反应获得的加标签的核苷的测序反应方法 |
| JP2020528062A (ja) * | 2017-07-27 | 2020-09-17 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ピペラジンヘテロアリール誘導体、その製造方法、およびその医薬での使用 |
| TW202412758A (zh) * | 2022-06-29 | 2024-04-01 | 香港商英矽智能科技知識產權有限公司 | Fgfr2與fgfr3抑制劑及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1150991B1 (en) | 1999-02-01 | 2004-04-07 | University of Virginia Patent Foundation | Compositions for treating inflammatory response |
| MXPA04002243A (es) * | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| ATE428711T1 (de) | 2003-12-11 | 2009-05-15 | Aventis Pharma Inc | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon |
| GB0328900D0 (en) | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
| US8304408B2 (en) * | 2007-05-24 | 2012-11-06 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| NZ582871A (en) | 2007-07-27 | 2011-09-30 | Sanofi Aventis | 1,2,3,4-Tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5- tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof |
| EP2229395A1 (en) * | 2008-01-17 | 2010-09-22 | Grünenthal GmbH | Substituted sulfonamide derivatives |
| WO2009097515A2 (en) * | 2008-01-30 | 2009-08-06 | Wyeth | [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
-
2010
- 2010-06-03 FR FR1054372A patent/FR2960876B1/fr not_active Expired - Fee Related
-
2011
- 2011-06-01 BR BR112012030697A patent/BR112012030697A2/pt not_active IP Right Cessation
- 2011-06-01 DK DK11781590.2T patent/DK2588480T3/en active
- 2011-06-01 KR KR1020127031424A patent/KR20130113928A/ko active Search and Examination
- 2011-06-01 LT LTEP11781590.2T patent/LT2588480T/lt unknown
- 2011-06-01 MX MX2012014084A patent/MX2012014084A/es active IP Right Grant
- 2011-06-01 EA EA201291364A patent/EA201291364A1/ru unknown
- 2011-06-01 EP EP11781590.2A patent/EP2588480B1/en active Active
- 2011-06-01 CN CN201180038277.8A patent/CN103168041B/zh not_active Expired - Fee Related
- 2011-06-01 NZ NZ603947A patent/NZ603947A/en not_active IP Right Cessation
- 2011-06-01 JP JP2013513006A patent/JP5995841B2/ja not_active Expired - Fee Related
- 2011-06-01 SG SG2012088795A patent/SG186143A1/en unknown
- 2011-06-01 ES ES11781590.2T patent/ES2603420T3/es active Active
- 2011-06-01 MA MA35524A patent/MA34360B1/fr unknown
- 2011-06-01 HU HUE11781590A patent/HUE030650T2/en unknown
- 2011-06-01 PE PE2012002257A patent/PE20130259A1/es not_active Application Discontinuation
- 2011-06-01 AU AU2011268651A patent/AU2011268651B2/en not_active Ceased
- 2011-06-01 CA CA2801154A patent/CA2801154C/en not_active Expired - Fee Related
- 2011-06-01 SI SI201131022A patent/SI2588480T1/sl unknown
- 2011-06-01 PL PL11781590T patent/PL2588480T3/pl unknown
- 2011-06-01 WO PCT/IB2011/001594 patent/WO2011161537A2/en active Application Filing
- 2011-06-01 PT PT117815902T patent/PT2588480T/pt unknown
- 2011-06-02 AR ARP110101901A patent/AR081832A1/es not_active Application Discontinuation
- 2011-06-03 TW TW100119696A patent/TWI487707B/zh not_active IP Right Cessation
- 2011-06-03 UY UY0001033428A patent/UY33428A/es unknown
-
2012
- 2012-10-31 TN TNP2012000520A patent/TN2012000520A1/en unknown
- 2012-11-22 DO DO2012000296A patent/DOP2012000296A/es unknown
- 2012-11-26 CR CR20120595A patent/CR20120595A/es unknown
- 2012-11-27 GT GT201200319A patent/GT201200319A/es unknown
- 2012-11-29 IL IL223364A patent/IL223364A/en not_active IP Right Cessation
- 2012-11-29 US US13/688,916 patent/US8791119B2/en not_active Expired - Fee Related
- 2012-11-30 NI NI201200176A patent/NI201200176A/es unknown
- 2012-11-30 CL CL2012003360A patent/CL2012003360A1/es unknown
- 2012-11-30 ZA ZA2012/09071A patent/ZA201209071B/en unknown
- 2012-12-03 CO CO12218640A patent/CO6602113A2/es active IP Right Grant
- 2012-12-03 EC ECSP12012322 patent/ECSP12012322A/es unknown
-
2014
- 2014-07-23 US US14/339,112 patent/US9233965B2/en not_active Expired - Fee Related
-
2016
- 2016-11-11 HR HRP20161494TT patent/HRP20161494T1/hr unknown
- 2016-11-16 CY CY20161101179T patent/CY1118512T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081832A1 (es) | Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida, su preparacion y su aplicacion en terapeutica | |
| ES2624795T3 (es) | Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| ES2521596T3 (es) | Combinación del compuesto GlyT1 con antipsicóticos | |
| ES2689037T3 (es) | Compuestos y composiciones antihelmínticas y procedimiento de utilización de los mismos | |
| AR116666A1 (es) | Compuestos heterocíclicos | |
| NI201000120A (es) | Derivados de ftalazinona | |
| CY1121599T1 (el) | Νεο παραγωγο αμινης ή αλας αυτου ως παρεμποδιστες tnf αλφα | |
| AR061946A1 (es) | Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y composiciones farmaceuticas | |
| BR112015032689A2 (pt) | composto heterocíclico fundido e uso em controle de pragas do mesmo | |
| CY1111308T1 (el) | Παρασκευη εσλικαρβαζεπινης και σχετικων ενωσεων με ασυμμετρη υδρογονωση | |
| AR069269A1 (es) | Derivados de 6- cicloamino -3- (piridin-il) imidazo (1,2-beta)- piridazina, su preparacion y su aplicacion en terapeutica | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| AR070648A1 (es) | Derivados de bencimidazol sustituido | |
| CO6190523A2 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| EA201170099A1 (ru) | Замещенные пиримидин-4-оновые производные | |
| AR061058A1 (es) | Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas | |
| AR065901A1 (es) | Derivados de pirrolipirimidina | |
| AR050283A1 (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeuticas. | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| JP2012131775A5 (ja) | カルバゾール化合物、発光素子、発光装置、電子機器および照明装置 | |
| AR095721A1 (es) | Derivados de piridina | |
| PE20151977A1 (es) | Nuevos derivados de purina | |
| AR075777A1 (es) | Derivados de benzotiazina, su preparacion y aplicacion como farmacos para la inhibicion de 11beta-hidroxiesteroide deshidrogenasa tipo i (11betahsd1) | |
| AR066603A1 (es) | Derivados de arilamida pirimidona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |